# Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

> **NCT02099071** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 65 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** ACT-389949 1 mg
- **DRUG:** ACT-389949 5 mg
- **DRUG:** ACT-389949 20 mg
- **DRUG:** ACT-389949 50 mg
- **DRUG:** ACT-389949 100 mg
- **DRUG:** ACT-389949 200 mg
- **DRUG:** ACT-389949 500 mg
- **DRUG:** ACT-389949 1000 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02099071
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02099071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02099071, "Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02099071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*